Lamifiban
- Level
- Commodity
- Parent
- 51131700
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51131729This classification denotes an antiplatelet agent with the molecular formula C24H28N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XOE28082S, chemically known as acetic acid, ((1-(2-((4-aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)-, (s)- but generally known as lamifiban, which bears US NIH Compound Identifier 71453. European Medicines Agency schedules Lamifiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08391MIG. The term LAMIFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). LAMIFIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lamifiban under HS 29333999 and SITC 51574. As of Q4 2014, LAMIFIBAN remains the US FDA Preferred Term for this commodity. Lamifiban bears US NLM identifiers UMLS ID C0380040 and NCI Concept Code C83862. SMILES: O(C1CCN(CC1)C(=O)C(NC(=O)C1CCC(CC1)C(=N)N)CC1CCC(O)CC1)CC(=O)O.
Same parent
Under 51131700 · 48Activities that produce or sell this
KBLI · 8Inherited from family 51130000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.